Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation
Annals of Hematology · 29.09.2026 · 105 (12)
DOI: 10.1007/s00277-026-07295-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Hematology, online erschienen am 29.09.2026. Verfasst von Jiayuan Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Although T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) were historically regarded as different manifestations of a single disease entity driven by immature T-lymphoblast proliferation, recent advances in molecular diagnostics and cytogenetic testing have revealed inherent differences in their molecular signatures and chromosomal profiles. Despite these differences, comparative data on clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT) between the two subtypes remain limited. To address this gap, we retrospectively analyzed 106 consecutive patients, including 71 with T-ALL and 35 with T-LBL, who underwent allo-HSCT at our institution between January 2010 and January 2025. No statistically significant differences were observed in overall survival (OS), disease-free survival (DFS), graft-versus-host disease–free, relapse-free survival (GRFS), cumulative incidence of relapse (CIR), or cumulative incidence of non-relapse mortality (NRM) between patients with T-ALL and T-LBL. Diagnosis was not associated with these outcomes in multivariable analyses. However, the association between diagnosis and OS, DFS, CIR, and NRM varied over time. At 6 months, the multivariable analysis showed worse OS in T-LBL (hazard ratio at the specified time [HR(t)], 2.41; 95% confidence interval [CI], 1.10–5.28; P = 0.028). At 36 months, T-LBL was associated with lower risks of DFS failure (HR(t), 0.16; 95% CI, 0.03–0.91; P = 0.039) and NRM (subdistribution hazard ratio at the specified time [sHR(t)], 0.06; 95% CI, 0.01–0.72; P = 0.026). The 36-month restricted mean survival time (RMST) for OS was 5.79 months shorter in T-LBL (95% CI, − 11.38 to − 0.19; P = 0.043), whereas DFS and GRFS RMST did not differ significantly. Results for most outcomes did not differ significantly between groups in either the PSM cohorts or the first complete remission subgroup, although moderate to severe chronic graft-versus-host disease (cGVHD) was less frequent in T-LBL. Complete case analyses for white blood cell (WBC) and lactic dehydrogenase (LDH) and analyses restricted to patients in complete remission with evaluable measurable residual disease (MRD) did not materially alter the diagnosis estimates. Overall, OS, DFS, CIR, NRM, and GRFS did not differ significantly between patients with T-ALL and T-LBL, although the effects of diagnosis on OS, DFS, CIR, and NRM changed during follow-up. These findings should be interpreted cautiously and confirmed in larger multicenter studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Nankai University, Tianjin, China.
- Medical School of Chinese PLA, Beijing, China.
- Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
- Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China. lipingruirui@163.com.
- Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China. guzhenyang@hotmail.com.
- School of Medicine, Nankai University, Tianjin, China. gaochunji301@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Guo, J., Huang, L., Li, Z., Zhang, A., Li, M., Zhang, L., Wang, L., Li, F., Wang, L., Jing, Y., Bo, J., Liu, D., Dou, L., Gu, Z., & Gao, C. (2026). Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 105(12). https://doi.org/10.1007/s00277-026-07295-4
Vancouver
Guo J, Huang L, Li Z, Zhang A, Li M, Zhang L, et al. Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation. Annals of Hematology. 2026;105(12). doi:10.1007/s00277-026-07295-4
BibTeX
@article{Guo2026,
author = {Guo, Jiayuan and Huang, Liuqing and Li, Zixuan and Zhang, Andi and Li, Meng and Zhang, Linlin and Wang, Lu and Li, Fei and Wang, Lili and Jing, Yu and Bo, Jian and Liu, Daihong and Dou, Liping and Gu, Zhenyang and Gao, Chunji},
title = {Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {12},
doi = {10.1007/s00277-026-07295-4}
}
EUVIMED